Back to Search

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors

  • Protocol Number: 202303122
  • Principal Investigator: Reimers, Melissa
  • Cancer Types: Gene & Cellular Immunotherapy

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions